Compare ENIC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENIC | PTGX |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.4B |
| IPO Year | 2015 | 2016 |
| Metric | ENIC | PTGX |
|---|---|---|
| Price | $4.41 | $120.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $108.23 |
| AVG Volume (30 Days) | 586.3K | ★ 705.9K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | N/A |
| Revenue This Year | $96,491.22 | $874.25 |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | ★ $101.18 | $2,455.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $49.86 |
| 52 Week High | $4.74 | $126.25 |
| Indicator | ENIC | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 50.70 | 66.64 |
| Support Level | $4.33 | $94.48 |
| Resistance Level | $4.73 | N/A |
| Average True Range (ATR) | 0.12 | 4.67 |
| MACD | -0.00 | 1.54 |
| Stochastic Oscillator | 54.14 | 77.87 |
Enel Chile SA is an electricity utility company engaged, through its subsidiaries and affiliates, in the generation, transmission, and distribution of electricity across Chile. The Company operates through two main segments: the Generation Business, which includes companies that own and operate power plants supplying electricity to the grid and generates the majority of revenue; and the Distribution and Network Business, which consists of companies operating under public utility concessions to distribute electricity to end customers.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.